Zeng Rong, Spolski Rosanne, Finkelstein Steven E, Oh SangKon, Kovanen Panu E, Hinrichs Christian S, Pise-Masison Cynthia A, Radonovich Michael F, Brady John N, Restifo Nicholas P, Berzofsky Jay A, Leonard Warren J
Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
J Exp Med. 2005 Jan 3;201(1):139-48. doi: 10.1084/jem.20041057.
Interleukin (IL)-21 is the most recently recognized of the cytokines that share the common cytokine receptor gamma chain (gamma(c)), which is mutated in humans with X-linked severe combined immunodeficiency. We now report that IL-21 synergistically acts with IL-15 to potently promote the proliferation of both memory (CD44high) and naive (CD44low) phenotype CD8+ T cells and augment interferon-gamma production in vitro. IL-21 also cooperated, albeit more weakly, with IL-7, but not with IL-2. Correspondingly, the expansion and cytotoxicity of CD8+ T cells were impaired in IL-21R-/- mice. Moreover, in vivo administration of IL-21 in combination with IL-15 boosted antigen-specific CD8+ T cell numbers and resulted in a cooperative effect on tumor regression, with apparent cures of large, established B16 melanomas. Thus, our studies reveal that IL-21 potently regulates CD8+ T cell expansion and effector function, primarily in a synergistic context with IL-15.
J Exp Med. 2005-1-3
Clin Cancer Res. 2011-7-7
J Immunol. 2006-11-1
Cancer Immunol Immunother. 2010-1-26
Front Oncol. 2025-5-21
Front Immunol. 2025-5-1
Mol Ther. 2025-4-2
Proc Natl Acad Sci U S A. 2004-2-17
Cancer Res. 2003-12-15
J Immunol. 2003-5-15
Nat Rev Immunol. 2003-4